Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Long-acting reversible contraception

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Long-acting reversible contraception. Displaying page 1 of 1.
    EudraCT Number: 2015-005551-27 Sponsor Protocol Number: CCD-06366AA1-01 Start Date*: 2017-12-11
    Sponsor Name:Chiesi Farmaceutici
    Full Title: A First in Human Randomised, Double-Blind, Placebo-Controlled Study of Single Ascending Doses in Healthy Male Volunteers and Repeated Ascending Dose in Asthmatic Patients Followed by a 3-Way Cross-...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD) Patients with Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004149-27 Sponsor Protocol Number: I13106870 Start Date*: 2009-01-06
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000053-21 Sponsor Protocol Number: FLUI-2014-134 Start Date*: 2015-05-05
    Sponsor Name:FLUIDDA nv
    Full Title: Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA/LAMA therapy using Functional Respiratory Imaging.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004527-32 Sponsor Protocol Number: SITADS Start Date*: 2016-11-22
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Kings College Hospital NHS Foundation Trust
    Full Title: Pilot randomised controlled trial of SITAgliptin for Depressive Symptoms in type 2 diabetes
    Medical condition: Depression in type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000042-12 Sponsor Protocol Number: A7881004 Start Date*: 2007-06-05
    Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, UK
    Full Title: A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACE...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004271-36 Sponsor Protocol Number: FLUI-2011-77 Start Date*: 2011-11-28
    Sponsor Name:FluidDA nv
    Full Title: Analysis of airway responses in severe COPD patients to Daxas®, using CT based functional respiratory imaging.
    Medical condition: COPD = Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001157-48 Sponsor Protocol Number: 20HH5896 Start Date*: 2020-07-28
    Sponsor Name:Imperial College London
    Full Title: Identifying a safe and tolerated dose of Imatinib for patients with Pulmonary Arterial Hypertension (PAH)
    Medical condition: Pulmonary Arterial Hypertension (Idiopathic, heritable, or assosicated with anorexigens)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036727 Primary pulmonary hypertension LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068739 Chronic thromboembolic pulmonary hypertension LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10050701 Congenital pulmonary hypertension PT
    20.0 10010331 - Congenital, familial and genetic disorders 10050701 Congenital pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001833-26 Sponsor Protocol Number: OC000459/019/15 Start Date*: 2015-07-21
    Sponsor Name:Atopix Therapeutics Ltd.,
    Full Title: THE EFFECT OF OC000459 ON EOSINOPHILIC AIRWAY INFLAMMATION AND ASTHMA CONTROL IN SUBJECTS WITH REFRACTORY EOSINOPHILIC ASTHMA: A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015470 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Oct 30 18:04:23 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA